Revenio Group Oyj/€REG1V
1D1W1MYTD1Y5YMAX
Capital at risk
About Revenio Group Oyj
Revenio Group Oyj is a company focused on providing medical diagnostic solutions, primarily in the fields of ophthalmology. It is known for its innovative products, such as tonometers for eye pressure measurements, which are important in glaucoma examinations. Founded in Finland, the company has its headquarters in Vantaa. Revenio leverages its specialized expertise in medical technology to address specific healthcare needs, with a strategic focus on precision, reliability, and ease of use in its devices. The company's geographic footprint extends across multiple international markets, facilitated by a network of distributors and partners.
- Ticker
- €REG1V
- Sector
- Health
- Primary listing
- XHEL
- Employees
- 765
- Headquarters
- Vantaa, Finland
- Website
- www.reveniogroup.fi
REG1V Metrics
BasicAdvanced
€388M
27.09
€0.49
0.88
-
Price and volume
Market cap
€388M
Beta
0.88
52-week high
€23.20
52-week low
€12.24
Average daily volume
128K
Financial strength
Current ratio
0.583
Quick ratio
0.335
Long term debt to equity
0.86
Total debt to equity
1.731
Dividend payout ratio (TTM)
0.30%
Profitability
EBITDA (TTM)
20.1
Gross margin (TTM)
67.85%
Net profit margin (TTM)
10.54%
Operating margin (TTM)
14.09%
Effective tax rate (TTM)
28.46%
Revenue per employee (TTM)
€160,000
Management effectiveness
Return on assets (TTM)
3.57%
Return on equity (TTM)
10.33%
Valuation
Price to earnings (TTM)
27.089
Price to revenue (TTM)
2.857
Price to book
2.68
Price to tangible book (TTM)
-2.41
Price to free cash flow (TTM)
43.007
Free cash flow yield (TTM)
2.33%
Free cash flow per share (TTM)
0.31
Growth
Revenue change (TTM)
15.97%
Earnings per share change (TTM)
-27.25%
3-year revenue growth (CAGR)
8.25%
10-year revenue growth (CAGR)
19.02%
3-year earnings per share growth (CAGR)
-11.88%
10-year earnings per share growth (CAGR)
9.46%
3-year dividend per share growth (CAGR)
6.92%
10-year dividend per share growth (CAGR)
9.15%
Bulls say / Bears say
Completion of the Visionix acquisition for an enterprise value of €290 m (consideration €250 m) creates a combined entity with pro forma sales exceeding €250 m and targets over €20 m of EBITDA synergies by 2029 (MarketScreener)
Net sales rose 48.1% year-on-year to €39.3 m in Q2 2026 following Visionix consolidation, demonstrating robust top-line growth momentum in key markets (MarketScreener)
Revenues for full-year 2026 are guided at €190–205 m (exchange-rate adjusted), reflecting management’s confidence in post-acquisition growth and successful synergy execution (MarketScreener)
Adjusted operating profit margin fell to 14.6% in Q2 2026 from 24.7% a year earlier, highlighting margin pressure from acquisition-related integration costs (MarketScreener)
Operating cash flow swung to –€5.8 m in H1 2026 from +€11.4 m in H1 2025, raising liquidity concerns ahead of the planned €80 m rights issue to strengthen the balance sheet (MarketScreener)
Gearing surged to 159.2% as of June 30, 2026 from –1.3% at end-2025, reflecting significant leverage taken on to finance the Visionix acquisition and potentially limiting financial flexibility (MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Upcoming events
No upcoming events
Funds containing REG1V
AllEURGBPUSD
Fund name | Fund size | €REG1V weighting |
|---|---|---|
Vanguard ESG Global All Cap€V3AA | €1.1B | 0.00% |
Vanguard ESG Global All Cap£V3AB | £905M | 0.00% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.00% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.